News Archive

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which Kolltan will in-license a monoclonal antibody targeting the Her3 receptor tyrosine kinase from MedImmune. Based on the current program status, Kolltan anticipates initiating Phase 1 clinical testing of this product in the first quarter of 2014.

“This in-licensing opportunity exemplifies our leadership in and focus on receptor tyrosine kinases and their key role in oncology and other serious diseases,” commented Dr. Jerry McMahon, Kolltan’s President and Chief Executive Officer. “Kolltan will apply its extensive scientific expertise and R&D drug development experience to prepare for entry into the clinic, including a focus on patient selection strategies. Kolltan is excited to advance this innovative product candidate into clinical testing for the broad potential treatment of cancer patients where this target plays a role.”

Maryland’s venture capital fund has announced that two tech companies in the state will get a total of $350,000.

Gov. Martin O’Malley made the announcement on Monday.

A Baltimore firm called SocialToaster has received approval for $200,000. The company specializes in social media and customer engagement.

A new class of medicines could give doctors the ability to awaken underperforming genes in patients who currently have no treatment options.

Boston-area startup RaNA Therapeutics is developing a novel kind of medicine that can boost the activity of genes that may be silenced or underactive and thus cause disease. The medicine would use a small RNA-like molecule that blocks the function of a long RNA molecule that is hampering the expression of such a gene.

Becton, Dickinson and Company is one of domain players of insulin syringes and other delivery devices, referring to the pie chart, Market Shares of the leading suppliers of Insulin Syringes and other delivery devices, 2009. Today, the market shares accounts 45% in the world, 80% in U.S. and Europe .

Medtronic has entered into an innovative partnership with The Johns Hopkins University, agreeing to provide $200,000 a year for up to three years and skilled mentoring to help biomedical engineering students design new healthcare solutions for underserved patients in developing countries.

The partnership was announced recently by Omar Ishrak, Medtronic’s chairman and chief executive officer, during his keynote address at the university’s annual Biomedical Engineering Design Day event. During his talk, Ishrak called attention to the need to improve access, outcomes, and the efficiency of healthcare solutions in developing regions of countries such as India, China, and Brazil.

QIAGEN N.V. announced a partnership with Exosome Diagnostics Inc. to develop and commercialize high-performance sample preparation kits for the processing of nucleic acids from exosomes.

According to a release, combining the Exosome Diagnostics platform technology approach with select QIAGEN consumables and automation platforms has the potential to allow researchers, drug developers and doctors to take repeated, real-time genetic “snapshots” of disease from patients’ blood, urine or cerebrospinal fluid without the need for tissue biopsy. The companies are targeting initial product launches in the first half of 2014. Financial terms were not disclosed.

No, you didn’t fall off the list, your SBIR Insider has been silent since February 28, 2013. There is a lot of SBIR news to report but first I owe you an explanation of my absence.

Those of you who are “mature” enough to remember the ever garrulous Howard Cosell, may recall the Larry Holmes / Tex Cobb fight in 1982 that ended Cosell’s illustrious boxing commentary career. Because the fight was so one sided, potentially tragic, a public mutilation, and just plain ugly (with the referee refusing to stop the fight), Cosell became so incensed that he fell mute from the middle of the fight on, never to announce another bout.

In 2012, Maryland ranked 5th in the number and total value of Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) program awards, after California, Massachusetts, Virginia and New York. Maryland firms received 265 awards valued at $94 million. A DBED analysis of SBIR/STTR Phase I and Phase II data shows that the number and value of awards decreased nationally in the last four years, and Maryland followed this trend. Even so, when compared to other states, Maryland consistently ranked within the top five recipients of SBIR/STTR awards in both the number and the dollar value of awards received.

Three more biotechnology companies went public Thursday as startups continued to capitalize on strong demand for these offerings, a trend that’s giving life-sciences venture capitalists a much-needed lift.

Cellular Dynamics International Inc., Conatus Pharmaceuticals Inc. and Onconova Therapeutics Inc. debuted on Nasdaq Thursday. Their initial public offerings followed recent IPOs from venture-backed biotechs such as Agios Pharmaceuticals Inc., bluebird bio Inc., Esperion Therapeutics Inc., OncoMed Pharmaceuticals Inc. and Prosensa Holding BV.

Independence Blue Cross (IBC), Penn Medicine, and DreamIt Ventures today host “Demo Day” for 10 health care startup companies selected to participate in DreamIt Health, the first-ever Philadelphia-based health care accelerator. The event will be held from 10 a.m. to 2 p.m. at World Café Live! at 3025 Walnut Street in Philadelphia. The participants will each have seven minutes to present their business plans to potential investors and customers, mentors, and health care executives. Demo Day events are ideal opportunities for startups to begin raising money to launch their businesses and gauge interest among key audiences.

“As health care undergoes dramatic change, I believe that the health care companies that thrive will be those with a clear vision that move rapidly and innovate. The caliber of this group of entrepreneurs and the diverse health care companies they represent is very promising and we’re pleased to have played a part in helping them plan, develop, and now present their ideas,” said Daniel J. Hilferty, president and CEO of IBC. “We are committed to transforming our region into a magnet for health care innovation, investment and employment, and supporting bright, new ideas like those we nurtured through DreamItHealth will help us get there faster.”